Treatment-related changes in serum neutrophil gelatinase-associated lipocalin (NGAL) in psoriatic arthritis: results from the PIPA cohort study

References

• Gladman DD, Antoni C, Mease P, Clegg DO, Nash O. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64:14–17.
   Web of Science ®Google Scholar
• Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet 2018;391:2273–84.
   PubMed Web of Science ®Google Scholar
• Bhole VM, Choi HK, Burns LC, Kellet CV, Lacaille DV, Gladman DD, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology 2012;51:552–6.
   PubMed Web of Science ®Google Scholar
• Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front Physiol 2020;11:1–32.
   PubMed Web of Science ®Google Scholar
• Lu B, Hiraki LT, Sparks JA, Malspeis S, Chen C-Y, Awosogba JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis 2014;73:1914–22.
   PubMed Web of Science ®Google Scholar
• de Hair MJH, Landewé RBM, van de Sande MGH, van Schaardenburg D, van Baarsen LGM, Gerlag DM, et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 2013;72:1654–8.
   PubMed Web of Science ®Google Scholar
• Crowson CS, Matteson EL, Davis JM, Gabriel SE. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:71–7.
   PubMed Web of Science ®Google Scholar
• Lupoli R, Pizzicato P, Scalera A, Ambrosino P, Amato M, Peluso R, et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 2016;18:1–9.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lam KSL, Kraegen EW, Sweeney G, Zhang J, Tso AW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34–41.
   PubMed Web of Science ®Google Scholar
• Yan Q-W, Yang Q, Mody N, Graham TE, Hsu C-H, Xu Z, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56:2533–40.
   PubMed Web of Science ®Google Scholar
• Colak S, Omma A, Sandikci SC, Yucel C, Omma T, Turhan T. Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis. Bratislava Med J 2019;120:65–9.
   Google Scholar
• Wang D, Fang L, Pan G. Association of serum lipocalin-2 concentrations with psoriasis and psoriatic arthritis: an updated meta-analysis. Dis Markers 2019;2019:1–7.
   Web of Science ®Google Scholar
• Sokolova MV, Simon D, Nas K, Zaiss MM, Luo Y, Zhao Y, et al. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther 2020;22:1–8.
   PubMed Web of Science ®Google Scholar
• Shao S, Cao T, Jin L, Li B, Fang H, Zhang J, et al. Increased lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion. J Invest Dermatol 2016;136:1418–28.
   PubMedGoogle Scholar
• Hau CS, Kanda N, Tada Y, Shibata S, Uozaki H, Fukusato T, et al. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J Dermatol 2016;43:785–94.
   PubMed Web of Science ®Google Scholar
• Hioki T, Komine M, Ohtsuki M. Diagnosis and intervention in early psoriatic arthritis. J Clin Med 2022;6:2051.
   Google Scholar
• Ogdie A, Tillett W, Booth N, Howell O, Schubert A, Peterson S, et al. Usage of C-reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe. Rheumatol Ther 2022;15:285–93.
   Google Scholar
• Højgaard P, Christensen R, Dreyer L, Mease P, De Wit M, Skov L, et al. Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study. BMJ Open 2016;6:1–10.
   Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
   PubMed Web of Science ®Google Scholar
• Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75:811–8.
   PubMed Web of Science ®Google Scholar
• Detry MA, Ma Y. Analyzing repeated measurements using mixed models. JAMA 2016;315:407–8.
   PubMed Web of Science ®Google Scholar
• Jang Y, Lee JH, Wang Y, Sweeney G. Emerging clinical and experimental evidence for the role of lipocalin-2 in metabolic syndrome. Clin Exp Pharmacol Physiol 2012;39:194–9.
   PubMed Web of Science ®Google Scholar
• Pourani MR, Abdollahimajd F, Zargari O, Shahidi Dadras M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J Dermatolog Treat 2022;19:1967–74.
   Google Scholar
• Tsui FWL, Lin A, Sari I, Zhang Z, Tsui HW, Inman RD. Serial lipocalin 2 and oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis. Arthritis Res Ther 2021;14:141.
   Google Scholar
• Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol 2012;27:519–30.
   Google Scholar
• Torres-Salido MT, Cortes-Hernandez J, Vidal X, Pedrosa A, Vilardell-Tarres M, Ordi-Ros J. Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. Nephrol Dial Transplant 2014;1:1740–9.
   Google Scholar
• Abella V, Scotece M, Conde J, Gómez R, Lois A, Pino J, et al. The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. Biomarkers 2015;20:565–71.
   PubMed Web of Science ®Google Scholar